| Literature DB >> 10728957 |
M B Holmes1, B E Sobel, C P Cannon, D J Schneider.
Abstract
Patients receiving the oral glycoprotein IIb-IIIa inhibitor orbofiban in the OPUS -TIMI 16 trial had a paradoxical increase in platelet reactivity with respect to both fibrinogen binding and alpha-granule degranulation, suggesting a mechanism for the lack of efficacy of orbofiban in the trial. Thus, sensitive assays of platelet reactivity may be helpful in the design of further clinical studies and implementation of antiplatelet therapy in patients.Entities:
Mesh：
Substances：
Year: 2000 PMID： 10728957 DOI： 10.1016/s0002-9149(99)00778-x
Source DB: PubMed Journal: Am J Cardiol ISSN： 0002-9149 Impact factor: 2.778